News
Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous data from Akesoâs HARMONi-6 trial left them wanting.
FEATURED STORIES
PD-(L)1ĂVEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing through trials in lung cancer. But the potential of these drugs may be highest in cancers where angiogenesis and immune escape are tightly intertwined.
From Eli Lillyâs David Ricks to Pfizerâs Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025.
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncologyâs annual conference with data from their potential Keytruda rival, alongside Revolution Medicineâs groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
FDA veteran Peter Marks will now shape the future of Eli Lillyâs vaccines work after the buys of Curevo, LimmaTech Biologics and Vaccine Company for up to $3.8 billion total.
THE LATEST
Topline Phase 3 results of survodutideâlicensed to Boehringer Ingelheim from Zealand Pharmaâare more comparable to Novo Nordiskâs Wegovy than to Eli Lillyâs Zepbound, William Blair analysts said on Tuesday.
Cancer cocktails pairing Modernaâs mRNA-4359 with Merckâs Keytruda and Marengoâs invikafusp alfa with Gilead Sciencesâ Trodelvy showed promising results, while a complex combination by Agenus and MiNK Therapeutics failed to elicit an overall response.
Weight loss giant Eli Lilly has penned a DNA editing deal with Profluent Bio, continuing its dealmaking spree as well as its commitment to artificial intelligence.
The FDA has renewed calls for Amgenâs Tavneos to be pulled from the market, saying it has discovered new evidence that study personnel doctored the results of the drugâs pivotal study in order to make it look effective.
Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46% nosedive for blockbuster heart failure drug Entresto.
Coultreon Biopharma is advancing assets that target salt-inducible kinases, proteins that drive inflammation and other immune-mediated conditions.
Fresh off a major clinical win, Revolution Medicines alleges that Erascaâs pancreatic cancer drug infringes on key patent protections and that the rival has âimproperly comparedâ the companiesâ assets publicly.
The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on its cornerstone immunology product.
Compass shares crash as âconfoundingâ survival data raise approvability questions for bispecific
While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
Sun Pharmaceutical is bringing Merck spinoff Organon into the fold, paying $11.75 billion in hopes of becoming a top global biosimilar player.